ABSTRACT
The 2022 mpox outbreak saw a rapid case surge among men-who-have-sex-with-men (MSM) in previously unaffected regions, driven by heterogeneity in sexual networks. A sudden decline followed, but its drivers remain unclear as it is difficult to distinguish the roles of vaccination, herd immunity, and behavioral changes. We developed a network model of mpox transmission among MSM based on sexual behavior data and fitted it to the Paris region epidemic. We studied whether the decline was driven by post-exposure prophylaxis (PEP) vaccination, immunity among highly active MSM, or behavioral changes. Behavioral shifts were modeled as either uniform or based on individual risk factors, like sexual activity or exposure to diagnosed cases. We used the cross-sectional 2023 ERAS survey to validate findings. Behavioral changes adopted by 49% (95%CI 47-51%) of MSM regardless of individual risk factors best explained the observed epidemic decline. These changes prevented an estimated 73% (28-99%) of mpox cases in summer 2022. Findings aligned with the ERAS survey data, showing that 46% (45-48%) of MSM reduced sexual partners. On the contrary, PEP vaccination and immunity among highly active MSM were insufficient to curb the outbreak. Widespread behavioral change was the primary driver of the mpox epidemic decline in the Paris region, before preventive vaccination or immunity could affect epidemic spread. These findings highlight the importance of effective risk communication and community engagement in outbreak management. Tailored public health responses that encourage adaptive behaviors, especially as vaccination efforts ramp up, are essential for supporting affected communities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially funded by: ANRS-MIE grant MPX-SPREAD (ANRS0292); ANR grant DATAREDUX (ANR-19-CE46-0008-03); EU Horizon 2020 grant MOOD (H2020-874850); EU Horizon Europe grants VERDI (101045989) and ESCAPE (101095619).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All surveillance data were anonymised before use. Surveillance was considered as non interventional research only requiring the non opposition of the patient (article L1211 of the French public health code). The Comite de protection des personnes Ile de France IX (n 2014 A01605 42) authorized the PREVAGAY study. Inserm's Ethics Evaluation Committee (IRB00003888 avis n 23 989) approved the ERAS study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵+ ISI Foundation, Turin, Italy
Data Availability
Data from PREVAGAY and ERAS studies can be made available to researchers upon request to Annie Velter, subject to approval of the proposed analyses and agreement to adhere to security, confidentiality, and collaborative conditions.
